Mencevax

Description

Mencevax™ ACWY is a lyophilised preparation of purified polysaccharides from Neisseria meningitidis (meningococcus) of serogroup A, C, W135 and Y.  It is indicated for the active immunisation of adults and children over two years of age against meningococcal meningitis. The vaccine is particularly recommended for subjects at risk, for example those living in or visiting areas where the disease is epidemic or highly endemic.

Immunization Guidline

One immunising dose of the reconstituted vaccine is contained in 0.5 ml. In adults and children over 5 years of age, immunity will persist for up to 3 years. Mencevax™ ACWY should under no circumstances be administered intravascularly but always subcutaneously.

Additional information

manufacturer

GlaxoSmithKline

country-of-manufacture

Belgium

vaccine-type

Meningococcal

pharmaceutical-form

Lyophilized

package-size

1 Dose, 5 Dose

route-of-administration

Subcutaneous

preservative

None, Phenol

Contraindications

The administration of Mencevax™ ACWY should be postponed in subjects
suffering from acute severe febrile illness. However, the presence of a minor infection such as a cold, should not result in the deferral of vaccination.